Formulation & Evaluation of Sustained Release Matrix Tablet Of Carbamazepine
Keywords:
Carbamazepine, sustained release matrix tablet, epilepsy and HPMCAbstract
Monolithic matrix tablets of carbamazepine were formulated as sustained release tablet employing HPMC polymer and the sustained release behavior of the fabricated tablet was investigated. Sustained matrix tablet contain 200 mg of carbamazepine were developed using different grade of HPMC alone or in combination. Tablets were prepared by direct compression. Formulation was optimized on the basis of acceptable tablet properties and in-vitro drug release. The resulting formulation produced robust tablets with optimum hardness, consistence weight uniformity and low friability. The result of dissolution study indicated that formulation C07 the most successful of the study, exhibited drug release pattern very close to USP data for carbamazepine extended release tablet. A decrease in release kinetic of drug was observed on increasing polymer ratio.
Downloads
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).